MDM2 and leukemia: RG7112, the first small-molecule MDM2 antagonist in clinical testing, demonstrated significant gastrointestinal and hematopoietic side effects but only modest clinical activity in phase I clinical trials conducted in adult patients with liposarcoma or leukemia [40, 41].